DBV Technologies S.A. (DBVT) vs Faeth Therapeutics (FTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 121.4% versus a loss of 31.4%. Over five years, DBVT leads with a -7.8% price change compared with -83.7% for FTH. Faeth Therapeutics is the larger company by market cap ($643.9 million vs $614.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | FTH |
|---|---|---|
| Share price | $9.77 | $24.92 |
| Market cap | $614.03M | $643.94M |
| 1-day change | -2.10% | -7.33% |
| YTD return | -49.03% | +133.55% |
| 1-year return | -31.39% | +121.39% |
| 5-year return | -7.83% | -83.67% |
| EPS (TTM) | $-3.50 | $-60.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.19 | $42.14 |
| 52-week low | $9.64 | $7.45 |
| Distance from 52-week high | -62.69% | -40.87% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +295.39% | +127.41% |
| Average volume | 331.54K | 351.88K |
| Shares outstanding | 62.85M | 25.84M |
| Employees | 170 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed DBVT by 152.8 percentage points over the past year.
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 170 employees
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
DBVT vs FTH FAQ
Which is bigger, DBV Technologies S.A. or Faeth Therapeutics?
Faeth Therapeutics (FTH) is larger, with a market capitalization of $643.94M compared with $614.03M for DBV Technologies S.A. (DBVT).
Which stock has performed better over the past year, DBVT or FTH?
FTH returned +121.39% over the past 12 months, compared with -31.39% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Faeth Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for DBV Technologies S.A. and Biotechnology: Pharmaceutical Preparations for Faeth Therapeutics.